Boulevard Bio

About Boulevard Bio

Boulevard Bio is a clinical-stage precision immunology company focused on developing therapies for B cell–driven autoimmune diseases. The company was incubated and is backed by Deerfield Management, a healthcare investment firm, combining the agility of a startup with the strategic resources of an established investor. Boulevard Bio was established by pioneers in B cell biology and is guided by veteran biotech executives. The company maintains a low public profile, focusing its efforts on advancing its therapeutic pipeline. The company's strategy involves accelerating innovation by acquiring and in-licensing promising external assets alongside internal development. A significant strategic move was the June 2026 agreement to license the global rights for MTS-128, a preclinical trispecific T-cell engager (TCE), from Metis TechBio. This deal, valued at up to $1.6 billion, provides Boulevard Bio with an asset developed using an AI-driven platform to target autoimmune diseases. Boulevard Bio's pipeline is led by a highly differentiated BAFF/APRIL dual inhibitor designed for subcutaneous administration. This lead candidate is being advanced with an accelerated clinical path to potentially establish a new standard of care in IgA Nephropathy (IgAN), an autoimmune disease with significant unmet medical need. Beyond its lead asset and the recently acquired TCE, the company's pipeline includes two additional programs centered on B cell reset and the combination of B cell biology with other disease drivers. Keywords: Precision immunology, B cell therapies, autoimmune diseases, Deerfield Management, clinical-stage biotechnology, BAFF/APRIL inhibitor, IgA Nephropathy, IgAN, T-cell engager, TCE, immunotherapy, biopharmaceutical, MTS-128, Metis TechBio, B cell biology, subcutaneous administration, B cell reset, antibody-drug conjugates, immunology R&D, autoimmune treatment